Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT03055338
PHASE2

An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)

Sponsor: Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

This will be a randomized, placebo-controlled, parallel-group, multi-site, double-blind trial of elpipodect compared with placebo, using Risperidone as an active control. The participants will be adult subjects experiencing an acute episode of schizophrenia, according to the criteria specified in the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. (DSM-5). This study will be up to 7 weeks in duration, with up to 7 site visits for each participant. The study will consist of a Screening/tapering period (up to one week long), a 4-week treatment period, and a 14-day follow-up period. The primary objective will be to assess symptoms of schizophrenia at 4 weeks, and to assess safety and tolerability during treatment and post-treatment follow-up. The secondary objective will be to assess the severity of schizophrenia at 4 weeks. The primary hypothesis is that elpipodect is superior to placebo in reducing the overall symptoms of schizophrenia as assessed by the mean change from baseline in the Positive and Negative Syndrome Scale (PANSS) total score after 4 weeks of treatment.

Official title: A Phase IIa, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of the Efficacy and Safety of MK-8189 Using Risperidone as an Active Control in Subjects Experiencing an Acute Episode of Schizophrenia

Key Details

Gender

All

Age Range

18 Years - 50 Years

Study Type

INTERVENTIONAL

Enrollment

224

Start Date

2017-03-08

Completion Date

2018-01-09

Last Updated

2026-04-29

Healthy Volunteers

No

Interventions

DRUG

Elpipodect

Oral CR tablets (4 mg) administered QD at the following dose strengths: 4 mg (1 tablet); 8 mg (2 tablets); 12 mg (3 tablets)

DRUG

Risperidone

Oral capsules (2 mg) administered QD at the following dose strengths: 2 mg (1 capsule); 4 mg (2 capsules); 6 mg (3 capsules)

DRUG

Placebo matching MK-8189

Oral placebo tablet(s) matching the MK-8189 tablet, administered QD.

DRUG

Placebo matching risperidone

Oral placebo capsule(s) matching the risperidone capsule, administered QD.

Locations (28)

Woodland International Research Group, LLC ( Site 0001)

Little Rock, Arkansas, United States

Woodland Research Northwest, LLC ( Site 0014)

Rogers, Arkansas, United States

CITRIALS ( Site 0013)

Bellflower, California, United States

Comprehensive Clinical Development ( Site 0049)

Cerritos, California, United States

Collaborative Neuroscience Network, LLC ( Site 0057)

Garden Grove, California, United States

Behavioral Research Specialists, LLC ( Site 0006)

Glendale, California, United States

Synergy East ( Site 0003)

Lemon Grove, California, United States

NRC Research Institute ( Site 0043)

Orange, California, United States

CNRI - Los Angeles, LLC ( Site 0026)

Pico Rivera, California, United States

Artemis Institute for Clinical Research ( Site 0027)

San Diego, California, United States

Schuster Medical Research Institute ( Site 0032)

Sherman Oaks, California, United States

Collaborative Neuroscience Network, LLC ( Site 0046)

Torrance, California, United States

Larkin Community Hospital Behavioral Health Services ( Site 0020)

Hollywood, Florida, United States

Clinical Research Centers of America, LLC ( Site 0038)

Oakland Park, Florida, United States

Aspire Health Partners ( Site 0016)

Orlando, Florida, United States

Radiant Research - Atlanta ( Site 0008)

Atlanta, Georgia, United States

Atlanta Center For Medical Research ( Site 0056)

Atlanta, Georgia, United States

Alexian Center for Psychiatric Research ( Site 0015)

Hoffman Estates, Illinois, United States

Lake Charles Clinical Trials, LLC ( Site 0040)

Lake Charles, Louisiana, United States

CBH Health, LLC ( Site 0022)

Gaithersburg, Maryland, United States

Precise Research Centers ( Site 0018)

Flowood, Mississippi, United States

Psych Care Consultants Research ( Site 0025)

St Louis, Missouri, United States

St. Louis Clinical Trials, LLC ( Site 0012)

St Louis, Missouri, United States

Altea Research Institute ( Site 0017)

Las Vegas, Nevada, United States

Radiant Research -CliniLabs ( Site 0037)

New York, New York, United States

Midwest Clinical Research Unit ( Site 0041)

Dayton, Ohio, United States

InSite Clinical Research ( Site 0033)

DeSoto, Texas, United States

Pillar Clinical Research, LLC ( Site 0004)

Richardson, Texas, United States